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To understand how extracellular vesicle (EV) subtypes differentially activate monocytes, a 
series of in vitro studies were performed. We found that plasma-EVs biased monocytes 
toward an M1 profile. Culturing monocytes with granulocyte-, monocyte-, and endothelial- 
EVs induced several pro-inflammatory cytokines. By contrast, platelet-EVs induced TGF-β  
and GM-CSF, and red blood cell (RBC)-EVs did not activate monocytes in  vitro. The 
scavenger receptor CD36 was important for binding of RBC-EVs to monocytes, while 
blockade of CD36, CD163, CD206, TLR1, TLR2, and TLR4 did not affect binding of 
plasma-EVs to monocytes in  vitro. To identify mortality risk factors, multiple soluble 
factors and EV subtypes were measured in patients’ plasma at intensive care unit 
admission. Of 43 coagulation factors and cytokines measured, two were significantly 
associated with mortality, tissue plasminogen activator and cystatin C. Of 14 cellular 
markers quantified on EVs, 4 were early predictors of mortality, including the granulocyte 
marker CD66b. In conclusion, granulocyte-EVs have potent pro-inflammatory effects on 
monocytes in vitro. Furthermore, correlation of early granulocyte-EV levels with mortality 
in critically ill patients provides a potential target for intervention in management of the 
pro-inflammatory cascade associated with critical illness.
Keywords: extracellular vesicles, monocytes, granulocytes, exosomes, microvesicles, mortality, intensive care 
unit, receptor
inTrODUcTiOn
Extracellular vesicles (EVs) are double membrane vesicles that can be released from virtually all 
cell types under physiological and pathological conditions and may be detected in blood and other 
body fluids (1, 2). The role of EVs in cell–cell communication and immunity is a new area in biol-
ogy and medicine, and immunosuppressive and immunostimulatory roles have been attributed to 
EVs (3–6). We previously showed that EVs from stored leukoreduced blood are heterogeneous and 
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originate from multiple cell types. We observed that monocytes 
bind to and engulf EVs, and T cell response modulation by EVs 
is indirect and mediated via monocyte activation (7). Red blood 
cell (RBC)-EVs have been described as immunosuppressive or 
immunostimulatory in separate studies (8, 9). The literature is also 
conflicting on the stimulatory vs. suppressive effect of platelet-
EVs on monocytes and macrophages (10, 11).
Understanding how EV subtypes interact with immune 
cells would better allow their manipulation in disease states, 
as several mechanisms of uptake have been described for EVs. 
EV surface proteins can play an important role in EV uptake, as 
treatment of EVs with proteinase K decreases the uptake of EVs 
by ovarian cancer cells (12). Phagocytosis, clathrin-mediated 
endocytosis, caveolin-mediated endocytosis, and membrane 
fusion are suggested mechanisms for EV uptake (13). It is 
believed that adhesion molecules, integrins, and lectins play 
a role in EV uptake (13–15). Proteoglycans such as heparin 
sulfate may also play a role in EV uptake, as treatment of cells 
with a heparin sulfate mimetic reduces EV uptake (16). The 
role of TLRs in EV uptake has also been studied, and the data 
in the literature on TLRs are conflicting (17, 18). In general, 
EV uptake can involve several receptors (12, 19–24). The role 
of scavenger receptors in EV uptake is not well studied, but 
it has been shown that endothelial-EVs bind to the scavenger 
receptor CD36 on platelets and contribute to thrombosis in 
mice (25).
Increased levels of particular EV subtypes have been asso-
ciated with specific diseases, and EV subtypes may serve as 
novel biomarkers. The plasma level of CD31+ EVs is associated 
with increased risk of cardiovascular death (26). Tissue factor 
(CD142)-positive EVs derived from endothelial cells and mono-
cytes in sickle cell disease contribute to thrombin generation 
and coagu lation (27). In a study of critically ill patients, the ratio 
of platelet-EVs to platelet count was associated with mortality, 
primarily driven by an inverse relationship between platelet count 
and mortality (28). In critically ill burn patients, white blood cell 
(WBC)- and granulocyte-EVs at intensive care unit (ICU) admis-
sion are associated with subsequent mortality (29).
Using RNA sequencing and global transcriptomic analyses, 
here we show that plasma-EVs bias primary monocytes toward 
an M1 profile, which leads to generation of a dominant inflam-
matory response. We also show that whether EVs induce pro- or 
anti-inflammatory responses in monocytes depends on their 
cell of origin. Finally, we demonstrate that a group of scavenger 
receptors were regulated in monocytes stimulated with EVs, and 
that RBC-EVs bind monocytes at least in part via the scavenger 
receptor CD36. We enrolled a subset of 100 critically ill subjects 
from three of the clinical sites participating in the Age of BLood 
Evaluation (ABLE) trial and measured a broad array of immune 
and coagulation parameters to determine if the age of blood 
transfused affected these parameters, and secondarily whether 
any of the parameters predicted subsequent mortality (30). We 
showed that in addition to cystatin C and tissue plasminogen 
activator (TPA), EVs expressing CD66b (granulocyte), CD15 
(granulocyte and monocyte), CD11b (adhesion molecule), and 
CD62P (activated platelets and endothelial cells) are early pre-
dictors of mortality in ICU patients.
MaTerials anD MeThODs
study samples
For in vitro experiments Trima filters (discarded byproducts of 
platelet apheresis) were used to generate large stocks of stored 
peripheral blood mononuclear cells (PBMCs). Fresh blood from 
six healthy donors was used for isolation of granulocytes to gen-
erate pure granulocyte-EVs. To purify RBC- and platelet-EVs, 
RBC units and platelet units were washed by automation and 
stored for 21 and 5 days, respectively. All filters and units were 
de-identified and acquired from Blood Centers of the Pacific 
(BCP). All study protocols were approved by the University of 
California, San Francisco Committees on Human Research.
Samples from the ABLE study were used for ex vivo experi-
ments. ABLE was a multicenter, randomized, controlled clinical 
trial that studied the effect of RBC unit storage time in 1,430 
critically ill patients who received RBC transfusion. PBMC sam-
ples from a subset of 100 patients in the ABLE trial were collected 
pre-transfusion and on days 2, 6, 28, and 180 post-transfusion. 
ABLE sites participating in this study included The Ottawa 
Hospital (General and Civic campuses) and the Institut de Car-
diologie et de Pneumologie de Québec, Université Laval. All 
patients from the ABLE trial were eligible to participate, with the 
exception of those with history of bone marrow transplantation. 
Plasma samples were used for measurement of EVs, cytokines, 
growth factors, and coagulation factors. In addition, clinical 
data were collected in the ABLE trial, including mortality and 
multiorgan dysfunction syndrome score. Samples were collected 
under informed consent and IRB approval in accordance with 
the Declaration of Helsinki. A group of 48 healthy control subjects 
was enrolled at Blood Systems Research Institute, with a blood 
sample collected at a single time point for analysis of EV subtypes 
in peripheral blood.
sample Processing
Plasma-EVs were isolated from ACD-treated blood using diff-
erential centrifugation. Plasma was separated at 1,000  g from 
cells and spun at 13,000 g to make platelet-free plasma (PFP). Six 
mL of PFP were added to 30 mL phosphate-buffered saline and 
spun for 1 h at 100,000 g. EV pellets were resuspended in 1 mL 
RPMI and stored at −80°C. Purified EVs were used for functional 
experiments.
For measurement of EV subtypes in peripheral blood, whole 
blood from 48 donors was collected in a citrate tube. Tubes were 
centrifuged at 2,500 g, and plasma was stored in 0.5 mL aliquots 
at −80°C until testing. Whole blood was collected in EDTA tubes 
from ABLE study subjects on day 0 (before transfusion) and on 
days 2, 6, and 28 after the first RBC transfusion. Collection tubes 
were centrifuged at 1,000  g to separate cells from plasma, and 
plasma was centrifuged at 13,000 g for removal of platelets and 
large fragments of cells. Aliquots of 0.5 mL PFP were stored at 
−80°C until testing.
generation of Pure eV subtypes Based on 
Their cell of Origin
Pure RBC-, platelet-, monocyte-, granulocyte-, and endothelial-
EVs were prepared for functional experiments. Monocytes were 
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isolated from PBMCs of healthy donors by double negative sele-
ction using an EasySep Human Monocyte Enrichment Without 
CD16 Depletion Kit (Stemcell Technologies), and they were 
cultured at 1 million cells/mL for 2 days to generate monocyte- 
EVs in the culture supernatant. Whole blood was treated with 
HetaSep (Stemcell Technologies) to sediment RBCs and isolate 
leukocytes. Granulocytes were isolated from leukocytes by double 
negative selection using an EasySep Human Pan-Granulocyte 
Isolation Kit (Stemcell Technologies) and were cultured at 1 
million cells/mL for 24 h to generate granulocyte-EVs. Washed 
leukoreduced RBC units were stored for 21 days in CP2D plus 
AS3 storage solution at 4°C to generate pure RBC-EVs. Platelet 
units were washed and stored for 5  days on a shaker at 25°C to 
generate platelet-EVs. Human umbilical vein endothelial cells 
(University of California, San Francisco Cell Culture Facility) were 
cultured to 90% confluence for 1 week to generate endothelial-
EVs. EV subtypes were isolated from monocyte, granulocyte, and 
endothelial cell culture supernatants, and from stored RBC units 
and stored platelets by differential centrifugation as described 
earlier, follo wed by storage at −80°C.
characterization of eVs
To characterize EVs from patients, PFP samples were stained 
and acquired as previously described (31) using 14 different 
fluorochrome-conjugated monoclonal antibodies in three sepa-
rate panels, including CD235a-FITC, CD62P-APC, CD3-PerCP/
Cy5.5, CD19-Alexa/700, CD28-FITC, CD16-V450, CD62L-APC, 
CD11b-PE/Cy7, CD66-PE (BioLegend), CD15-FITC (ExAlpha), 
CD152-APC, CD14-APC/Cy7, CD108a-PE, and CD41a-PerCP/
Cy5.5 (BD Biosciences). In normal donor samples CD142-PE 
(BioLegend) and CD154-APC (BD Biosciences) were substituted 
for CD14 and CD152, respectively. To reduce the background 
staining and as the size of small EVs fall below the detection limit 
of flow cytometer, stained EVs were diluted in PBS and were 
centrifuged for 5 min at 500 g using 0.22 µm Ultrafree MC-GV 
Centrifugal Filter Units (Millipore). Flow through (small EVs 
and unbound antibodies) was discarded, and stained large EVs 
were harvested in PBS from the top of the filter. Data were 
acquired using an LSR II flow cytometer (BD Biosciences). FSC/
SSC voltages were set to the highest values that excluded the 
majority of background noise (i.e., just below the voltage thre-
shold at which event rate surpassed 5 events/s while running 
a tube of PBS alone). Typically, this threshold occurred at FSC 
and SSC voltages of around 500–600 and 300–350, respectively. 
Gates were set using beads sized 100, 200, 240, 500, and 1,000 nm 
(Megamix-Plus SSC; BioCytex), and EVs were collected from 
the threshold to the 1,000 nm gate based on SSC. Analysis was 
performed using FlowJo 7.6.5 software (Tree Star).
isolation of PBMcs and Purification  
of Monocytes
Whole blood or leukocytes trapped in TRIMA filters were over-
laid on Ficoll-Paque (Sigma-Aldrich) and centrifuged for 30 min 
at 600 g. PBMC layers were harvested followed by washing and 
cryopreservation in fetal bovine serum (FBS) containing 10% 
DMSO. Isolation of monocytes from PBMCs was performed by 
double negative selection from PBMCs using the EasySep Human 
Monocyte Enrichment Without CD16 Depletion Kit (Stemcell 
Technologies).
stimulation of Monocytes With eVs
Extracellular vesicles were counted using Trucount Absolute 
Counting Tubes (BD Biosciences). To each Trucount™ tube, 50 µL 
sample and 350 µL PBS were added and samples were read imme-
diately on the flow cytometer. EV concentrations were calculated 
using the following equation:
 





 eads L of sample added/ µ .  
One million monocytes were cultured in 1 mL of 10% inac-
tivated exosome-free FBS (SBI) in RPMI (containing 10  mM 
N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid, 100 U/mL 
penicillin G, and 100 mg/mL streptomycin) in the presence or 
absence of one million plasma-EVs in a 5% CO2 incubator at 37°C 
for 1, 3, and 24 h. Each experiment was performed in duplicate 
wells, and cell culture supernatants (0.3 mL) were harvested for 
cytokine assays and cells were added to 0.7  mL QIAzol Lysis 
Reagent (Qiagen) for total RNA isolation. For experiments using 
individual EV subtypes, 1 million monocytes were cultured with 
1 million EVs of a given subtype (RBC-, platelet-, monocyte-, 
endothelial-, and granulocyte-EVs) for 24  h, and supernatants 
were harvested for cytokine assays. For some expe riments EVs were 
fractionated by size. Briefly, EVs were centrifuged at 500 g using 
0.22 µm Ultrafree MC-GV Centrifugal Filter Units (Millipore) to 
separate small and large EVs (enriched for exosomes and MVs, 
respectively). The small EVs (<220 nm) were collected in the flow 
through, and the large EVs (>220 nm) were recovered from the top 
of the filter. Each fraction was incubated with monocytes for 16 h 
followed by permeabilization of cells using Cytofix/Cytoperm Kit 
(BD Biosciences) and intracellular staining for TNF-α (-V421 
labeled, BioLegend).
gene expression Profiling With high 
Throughput sequencing
Total RNA from monocytes, EVs, and PBMC positive controls 
was extracted using the miRNeasy Mini Kit (Qiagen) with the 
optional on-column DNAse treatment step. RNA was quantified 
using a NanoDrop ND-1000 Spectrophotometer (NanoDrop 
Technologies) and integrity was assessed using an Agilent 2100 
Bioanalyzer (Agilent Technologies). For RNA-Seq experiments 
cDNA was generated using the Illumina TruSeq Stranded mRNA 
Library Prep Kit (Illumina Technologies), and 400 ng of total RNA 
was used as input. Single-read sequencing was performed using 
the Illumina HiSeq 2000 instrument to obtain 30–50 million 
single reads of 51 nucleotides. RNA-Seq data were preprocessed by 
adaptor trimming and low quality 3′-tail trimming (Phred > 20). 
The preprocessed reads were mapped using Tophat to the ref-
erence genome hg19. Gene level expression quantification in 
FPKM (Fragments Per Kilobase of transcript per Million mapped 
reads) was calculated using Cufflinks suite including Cufflinks, 
Cuffmerge, Cuffquant, and Cuffnorm. Significant changes in 
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transcript expression were quantified by t-test, which were adju-
sted by false discovery rate (FDR < 0.05). Gene annotations and 
GO terms were extracted from BioMart using the Bioconductor/
biomaRt package.
intracellular cytokine assays and  
Tlr Blocking antibodies
Intracellular staining of monocytes for detection of TNF-α was 
performed after stimulation of 1 million/mL monocytes with 
EVs as previously described (7). To test the efficacy of anti-TLR 
neutralizing antibodies, one million PBMCs were treated with 
1 µg/mL TLR1, TLR2, or TLR4 antibodies for 1 h, and then stimu-
lated with TLR agonists (InvivoGen) for 16 h. Synthetic tripal-
mitoylated lipopeptide Pam3CysSerLys4 (Pam3CSK4, 20 ng/mL) 
was used as a TLR1 and TLR2 agonist, and LPS (5 ng/mL) was used 
as a TLR4 agonist. Finally, cells were stained with CD14-APC/ 
Cy7 antibody (BioLegend) before permeabilization, then washed 
and stained for TNF-α, and run on the flow cytometer.
Measurement of cytokines in supernatant 
of Monocytes stimulated With eVs
A Milliplex MAP Kit (Millipore) was used to measure the level 
of 13 cytokines and growth factors in culture supernatants 
of monocytes stimulated with plasma-EVs (GM-CSF, IFNγ, 
IL-10, IL-12p70, IL-13, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, 
and TNF-α). A second Milliplex MAP kit from the same manu-
facturer was used to measure the level of 12 cytokines in super-
natants of monocytes stimulated with EV subtypes (IFNγ, IL-10, 
sCD40L, IL-1RA, IL-1α, IL-1β, IL-6, MIP-1α, TNF-α, MIG, 
GM-CSF, and TGF-β). A Bio-Plex 200 instrument (Bio-Rad) was 
used for data acquisition.
cell surface expression of scavenger 
receptors and Tlrs
Cell surface expression of scavenger receptors CD36, CD163, and 
CD206, and cell surface expression of TLR1, TLR2 and TLR4 
on monocytes were assessed by staining PBMCs with CD14-
PerCP/Cy5.5, CD36-PE, CD163-APC, CD206-Alexa Fluor 488, 
TLR2-PE, TLR4-APC (BioLegend), and TLR1-FITC (Invivogen) 
fluorochrome-conjugated antibodies according to the manufac-
turers’ instructions. Samples were fixed in 2% paraformaldehyde 
solution and were run on the flow cytometer. Percent expression 
of scavenger receptors and MFI of TLRs were measured after 
gating on CD14+ monocytes.
eV–Monocyte Binding assay
Plasma-EVs, aged RBC-EVs, or EV subtypes were stained with 
PKH26 Red Fluorescent Cell Linker Dye (Sigma-Aldrich). EVs 
were washed twice with 10% exosome-free FBS in RPMI to quench 
the unbound dye. Recombinant annexin V (BD Biosciences) or 
functional grade blocking monoclonal antibodies against phos-
phatidylserine (PS) (Millipore), CD36 (Stemcell Technologies), 
CD163, CD206 (BioLegend), TLR1 (Invivogen), TLR2, and TLR4 
(BioLegend) were used at multiple concentrations (0.01–2.0 µg/
mL) to block EV–monocyte binding. In some experiments, EVs 
were incubated with annexin V or anti-PS antibody. In other 
experiments PBMCs were incubated with monoclonal antibodies 
against CD36, CD163, CD206, TLR1, TLR2, or TLR4 in a 5% CO2 
incubator at 37°C for 1 h. PBMCs (500,000) were cultured with 
EVs, in a final volume of 0.5 mL for 24 h. PBMCs were stained 
with CD14-PerCP/Cy5.5 (BioLegend) and were fixed in 2% para-
formaldehyde solution. PBMCs were subject to flow cytometry, 
and percent binding of monocytes to EVs was measured by gating 
on CD14+ cells.
Measurement of cytokines and 
coagulation Factors
PFP from 100 ABLE study subjects was analyzed for levels of 
immune and coagulation markers. To determine the inflamma-
tory and coagulation profile of PFP, a total of 43 diff erent markers 
were measured, including 16 coagulation factors: prothrombin 
time, partial thromboplastin time, D-dimer concentration, 
factor II, factor V, factor VII, factor VIII/40, factor IX/20, fac-
tor X, antithrombin III, protein C, fibrinogen concentration, 
thrombomodulin, endothelial cell protein C receptor, TPA, and 
plasminogen activator inhibitor type-1 (PAI-1). The markers of 
coagulation were analyzed on a Stago or Dade Behring-Siemens 
device. Coagulation factors Va, VIIIa, VII, as well as antithrombin III, 
prothrombin time, partial thromboplastin time, TPA, D-dimer, 
and protein C were measured on a Diagnostica Stago™ coagula-
tion analyzer. Concentrations of prothrombin fragments 1 + 2, 
soluble thrombomodulin, PAI-1, soluble endothelial protein 
C receptor, and cytokines were measured using commercially 
available ELISA kits. In addition, 27 cytokines were measured 
using Milliplex MAP kit (Millipore): GM-CSF, IL-12p70, IL-17A, 
IL-1β, IL-2, IL-21, IL-23, IL-6, IL-7, IL-8, ITAC, MIP-1α, MIP-
1β, TNF-α, EGF, FGF, IFN-γ, IP-10, VEGF, β2-microglobulin, 
cystatin C, myeloperoxidase, PAI-1, PDGF-AB/BB, RANTES, 
sICAM-1, and sVCAM–1. A Bio-Plex 200 instrument (Bio-Rad) 
was used for cytokines data acquisition.
Data analysis
Supervised gene analysis was performed on all genes that were 
mapped by high throughput sequencing and used in this paper. 
FDRs were computed using the Benjamini–Hochberg procedure 
to adjust for multiple comparisons in the RNA-Seq data. The heat 
maps were generated using standardized Z-scores. GraphPad 
Prism v.6 was used for ANOVA and t-test analyses as noted in 
the figure legends. The significance of predictors of mortality was 
based on Cox regression analyses. The distribution of the data was 
analyzed, and for analytes with non-normally distributed data, 
values were log-transformed before analysis.
resUlTs
eV exposure initiates an M1 Phenotype 
gene expression Program
To better understand how EVs affect human immune cells, 
we performed transcriptomic analyses using RNA-Seq on 
monocytes at baseline and longitudinally after exposure to 
EVs derived from PFP. It has been shown that monocytes and 
monocyte-derived macrophages internalize EVs, which leads to 
FigUre 1 | (a) M1 and (B) M2 mRNA expression profile of extracellular vesicle (EV)-exposed monocytes. Monocytes were purified from peripheral blood 
mononuclear cells of five healthy donors and were cultured unstimulated or stimulated with plasma-EVs from five other healthy donors for 0, 1, 3, and 24 h. 
mRNA expression was determined by RNA-Seq and analyzed longitudinally for a panel of previously described M1 and M2-associated genes. Results for 
EV-incubated conditions were normalized to matched, unstimulated conditions at each time point and log2-transformed (*p < 0.05, **p < 0.01, and ***p < 0.001).
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their activation (11, 32, 33). Our prior work demonstrated that 
monocytes ingest EVs found in stored RBC units (7), therefore 
we focused our studies on this population of immune cells. It has 
been shown that several genes are expressed differentially during 
the process of monocyte polarization to M1 and M2 profiles, and 
that the M1 phenotype has pro-inflammatory effects, while the 
M2 phenotype possesses anti-inflammatory properties (34). We 
analyzed 53 genes that have been described as associated with the 
M1 profile and 43 genes associated with the M2 profile (34). From 
M1-associated genes, the mRNA of 19 genes were significantly 
upregulated at 3 and/or 24 h, including NAMPT, IL15RA, VCAN, 
CHI3L2, IL7R, IL2RA, PTX3, SLC2A6, BIRC3, SPHK1, TNF, 
EDN1, BCL2A1, CCR7, CCL20, IL6, INHBA, PFKFB3, and SLC7A5 
(Figure 1A). Three genes were downregulated at 1 and/or 3 h, 
including SLC31A2, PSMB9, and PSAM2. Analysis of M2 genes 
showed that the majority of M2-biasing genes with significant 
changes after EV exposure were downregulated (Figure 1B). We 
found that mRNA of 19 genes were downregulated, most notably 
at 3 h post EV exposure, including MSR1, CXCR4, CD302, GAS7, 
TPST2, CD36, MS4A6A, LTA4H, TLR5, SLC38A6, SLEC10A, LIPA, 
MS4A4A, SLCO2B1, LPAR6, TGFBI, ADK, HS3ST1, and HEXB. 
Only four M2-associated genes were upregulated, including 
FigUre 2 | Expression of cytokines, chemokines, and growth factors. Monocytes were purified from peripheral blood mononuclear cells of five healthy donors  
and were cultured unstimulated or stimulated with plasma-EVs from five other healthy donors for 0, 1, 3, and 24 h. Supervised gene analysis was performed, and 
significant changes in transcript expression quantified by t-test, which were adjusted by false discovery rate (<0.05). (a) Of the panel of genes for interleukins or 
their receptors, expression of 14 was significantly upregulated and of 3 was downregulated at 3 and/or 24 h in monocytes stimulated with EVs compared with 
paired unstimulated samples. (B) Of the chemokines and their receptors, expression of 14 was significantly upregulated and of 3 was downregulated at 3 and/or 
24 h. (c) mRNA expression of most interferons was not detectable, and of the detectable messages none was significantly different from unstimulated monocytes. 
(D) Supernatants were collected from the same cultures used for mRNA expression analysis. Results for stimulated conditions were normalized to unstimulated 
data and log2-transformed to show log-fold increase after stimulation (*p < 0.05, **p < 0.01, and ***p < 0.001).
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SLC4A7, CD209, CCL23, and HRH1. In summary, exposure of 
primary monocytes to EVs from plasma of healthy donors led 
to predominant upregulation of M1-associated genes (19 up and 
3 down) and downregulation of M2-associated genes (4 up and 
19 down), and the different regulation pattern of M1 and M2- 
associated genes was significant (p < 0.0001, Fisher’s exact test).
effector Molecules induced in Monocytes 
exposed to eVs
The RNA-Seq data were next analyzed to examine expression 
of cytokines and growth factors in more detail. From 36 known 
interleukins, message for 27 was detectable by high throughput 
sequencing. The mRNA expression of 14 interleukins and 
interleukin receptors was significantly upregulated at 3 and/
or 24 h (Figure 2A). We next looked at the gene expression of 
chemokines and found 24 mRNA transcripts that were detect-
able. Expression of 17 chemokines changed significantly, with the 
majority upregulated at 3 and/or 24 h (Figure 2B). In contrast 
to interleukins and chemokines, most interferon transcripts were 
not detectable, and of the five that were, none showed significant 
changes after EV exposure (Figure 2C).
To determine whether the changes in cytokine mRNA levels 
measured after monocyte exposure to EVs translated to changes 
in protein levels, the supernatants from the same stimulated 
monocytes were tested using a multiplex cytokine assay. The levels 
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of nine pro-inflammatory and four anti-inflammatory cytokines 
were measured at 0, 1, 3, and 24 h intervals in the supernatant 
of monocytes that were unstimulated or incubated with EVs 
isolated from normal donor plasma, and values were reported 
as a ratio of EV-exposed to unstimulated conditions at each time 
point (Figure 2D). Of the cytokines in the panel, mRNA levels 
of TNF and IL7 were elevated at 3 and 24 h after EV exposure, 
and mRNA from IL1B was elevated at 24 h. Protein levels of all 
these analytes were significantly elevated and concordant with the 
mRNA expression data, with the exception that IL6 mRNA was 
significantly elevated at 3 h while the elevation in IL-6 protein 
did not reach significance until 24 h. In addition, there were two 
cytokines with elevated protein levels at 3 h (IFN-γ and IL-8) and 
seven cytokines or growth factors with elevated protein levels at 
24 h that were either not significantly elevated or not detected in 
the mRNA analysis (IL-12p70, IFN-γ, IL-8, GM-CSF, IL-10, IL-
13, and IL-4). Examination of the mRNA and protein expression 
data of four representative cytokines revealed similar patterns 
between mRNA and protein expression for TNF-α, IL-1β, and 
IL-6, while increases in IL-10 were detectable at the protein 
but not mRNA expression level (Figure S1 in Supplementary 
Material). To determine whether EV-derived mRNA contributed 
to the signal in the RNA-Seq experiments, RNA was quantified 
in the monocyte preparations as well as separate PBMC, EV, and 
blank well conditions. Monocyte and PBMC controls showed 
peaks consistent with both small and mRNA species, while 
RNA was not detectable in EV preparations (Figures S2A,B in 
Supplementary Material). Overall, these data demonstrate that 
EVs found in healthy human plasma bias purified monocytes to 
a pro-inflammatory, M1 phenotype.
eV cell of Origin Determines effect  
of eVs on Monocytes
To better discriminate which EVs in plasma affect monocyte phe-
notype, we tested EVs derived from purified cell populations. 
Monocytes were stimulated with smaller EVs (<220 nm, enriched 
for exosomes) and larger EVs (>220 nm, enriched for microvesi-
cles) derived from granulocyte- and platelet-EVs for 16  h and 
monitored for TNF-α production. While both small and large EV 
fractions of granulocyte-EVs led to production of TNF-α, neither 
the small nor the large EV fractions of platelet-EVs induced the 
production of this pro-inflammatory cytokine (Figure 3A).
To more comprehensively measure EV subtype effects, puri-
fied monocytes were stimulated with RBC-, platelet-, monocyte-, 
endothelial-, or granulocyte-EVs, and a panel of 12 cytokines was 
measured in cell culture supernatants. Granulocyte-EVs were the 
most pro-inflammatory, inducing significant increases in mono-
cyte secretion of TNF-α, IL-1β, IL-6, MIP-1α, and GM-CSF 
(Figure  3B). Stimulation of monocytes with monocyte-EVs 
led to a significant increase in TNF-α, IL-6, and MIP-1α, and 
endothelial-EVs induced IL-6 and MIP-1α secretion. Stimulation 
of monocytes with platelet-EVs led to a significant increase of TGF-
β production. Analysis of all 12 cytokines revealed EV-induced 
changes in IL-10 and IL-1RA as well. Stimulation of monocytes 
with RBC-EVs did not change the secretion of cytokines that 
we measured (Figure 3C). In general, culturing monocytes with 
pure granulocyte-, monocyte-, and endothelial-EVs induced the 
secretion of several pro-inflammatory cytokines, in contrast to 
platelet- and RBC-EVs.
gene regulation and cell surface 
expression of scavenger receptors
The role of scavenger receptors in EV uptake is an area of active 
investigation (25, 35, 36). The mRNA expression of 24 scavenger 
receptors was measured by RNA-Seq to determine if these recep-
tors are regulated in monocytes after plasma-EV exposure. The 
mRNA expression of scavenger receptors SRA-1 (CD204), SRI-1 
(CD163), CD280, SRI-2 (CD163L1), SRB-2 (CD36), and SRJ-1 was 
downregulated, and the mRNA expression of SRF-1, and CD209 
was upregulated compared with the time-matched unstimulated 
condition (Figure S3A in Supplementary Material).
Several scavenger receptors were selected for analysis of pro-
tein expression and requirement for EV–monocyte binding. It has 
been shown that the scavenger receptor CD36 plays a role in thro-
mbosis in mice by binding to endothelial-EVs (25). Monocytes 
express the scavenger receptor CD163, which binds to hemo-
globin and haptoglobin-hemoglobin complex (37). As RBC-EVs 
are loaded with hemoglobin (38), we thought CD163 may play a 
role in EV binding. The mRNA expression of CD206, a receptor 
on monocytes that binds to mannose residues on bacteria (39), 
did not change in the RNA-Seq data, so this gene was included 
as a control (Figure S3B in Supplementary Material). To validate 
the mRNA findings, the cell surface expression of these receptors 
was determined. CD36 expression was decreased significantly 3 h 
after stimulation of monocytes with plasma-EVs. Expression of 
CD163 on the monocyte cell surface was decreased significantly 
at 3 and 24 h. Incubation of monocytes with plasma-EVs did not 
significantly change surface CD206 expression (Figure S3C in 
Supplementary Material). The surface expression of the scavenger 
receptors on monocytes was largely consistent with the mRNA 
expression data, with decreases seen after incubation with EVs.
gene regulation and cell surface 
expression of Toll-like receptors
The expression of TLR1, TLR2, and TLR4 mRNA was examined 
after exposure to plasma-EVs, as TLRs have been proposed as 
potential receptors for EVs (17, 18). The mRNA expression of 
TLR1 was downregulated at 3 h and upregulated at 24 h. The 
mRNA expression of TLR2 was upregulated at 3 and 24 h time 
points. Expression of TLR4 mRNA was downregulated at 3  h 
(Figure S3D in Supplementary Material). The surface expression 
of the TLR receptors was not concordant with the gene expres-
sion data. TLR1 surface expression did not differ after exposure 
to plasma-EVs, while TLR2 and TLR4 surface expression 
dropped at 3 h after EV exposure (Figure S3E in Supplementary 
Material).
Dependence of eV–Monocyte Binding  
on scavenger receptors and  
Toll-like receptors
Plasma-EVs  were incubated with PBMCs for 24 h with or without 
the addition of annexin V or antibodies to phosphatidyl serine or 
FigUre 3 | Continued
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several scavenger receptors. Blocking phosphatidyl serine, CD36, 
CD163, or CD206 did not affect EV–monocyte binding (Figure 4A). 
Similarly, blockade of TLR1, TLR2, or TLR4 had no effect on EV–
monocyte binding (Figure 4B). To ensure that the TLR antibodies 
had blocking activity, PBMCs from two subjects were activated with 
LPS or Pam3CSK4 and incubated with TLR4 or TLR1/2 antibodies, 
respectively. Monocyte TNF-α production was decreased 30–80% 
by the TLR antibodies (Figure S4A in Supplementary Material).
In addition to testing the ability of plasma-EVs to bind to 
monocytes, EVs derived from packed RBC units stored for 
FigUre 3 | Cytokine secretion by monocytes stimulated with subtypes of extracellular vesicles (EVs). Monocytes from peripheral blood mononuclear cells of six 
healthy donors were purified by negative selection. Six replicates of red blood cell-, platelet-, monocyte-, endothelial-, and granulocyte-EVs were prepared as described 
in the “Materials and Methods” section. Monocytes were cultured unstimulated or incubated with noted EV subtypes for 24 h. (a) Two independent experiments were 
run with small (enriched for exosomes) and large (enriched for MVs) fractions of granulocyte- and platelet-EVs, and the percentage of monocytes that produced TNF-α 
was measured by intracellular staining. Representative data showing intracellular cytokine staining of monocytes incubated with small and large fractions of 
granulocyte- and platelet-EVs. (B) Supernatants were collected at 24 h and were tested using a multiplex cytokine assay for 12 cytokines. Data were analyzed by 
ANOVA, and each condition was compared with the control condition using a Dunnett’s post-test. Data are shown for 6 of the 12 cytokines tested. (c) The log10 ratio 
of cytokines induced by incubating monocytes with five subtypes of EVs over the control condition is summarized in a heat map for all 12 cytokines (*p < 0.05, 
**p < 0.01, and ***p < 0.001).
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42 days were examined for their binding capacity to monocytes. 
As we previously published, the predominant EV subtype in 
these preparations was RBC-derived (7). Incubation of RBC 
unit-EVs with annexin V or anti-phosphatidyl serine antibody 
before incubation with monocytes significantly reduced binding 
to monocytes. Incubation of monocytes with anti-CD36 antibody 
also significantly reduced binding to RBC unit-EVs (Figure 4C).
Based on the data that CD36 blockade decreased interaction 
of RBC unit- but not plasma-EVs with monocytes, the binding 
capacity of, monocyte-, granulocyte-, RBC-, and platelet-EVs 
to primary monocytes was tested with or without monoclonal 
antibody blockade of scavenger receptor CD36. A representa-
tive titration of antibody is shown for purified RBC-EVs and 
monocytes (Figure S4B in Supplementary Material). Inhibition 
of binding of platelet-, granulocyte-, and monocyte-EVs to 
primary monocytes in PBMC cultures was tested, and none 
showed significant inhibition after incubation with anti-CD36 
antibody. These data show that CD36 is important in the binding 
of RBC-EVs to monocytes, but not for EVs derived from platelets, 
granulocytes, or monocytes (Figure 4D).
cellular Origin of eVs in healthy subjects
The plasma EV profile in 48 healthy subjects (42% male, median 
age 46) was examined using a panel of markers to identify EVs 
bearing markers of endothelial cells (CD142, CD62P), platelets 
(CD41a, CD62P), RBCs (CD235a, CD108a), and multiple WBC 
populations. Flow plots gated on EVs (events <1 μm by forward 
and side scatter, Figure 5A) revealed that the RBC marker CD235a 
and platelet marker CD41a were found on separate populations, 
while the RBC activation marker CD108a was only found on 
EVs also positive for CD235a (Figure 5B). Similarly, EVs bear-
ing the granulocyte marker CD66b were a separate population 
from those bearing CD62P (P-selectin), while those bearing the 
adhesion molecule CD11b were found almost exclusively on the 
granulocyte-EVs (Figure 5C). Platelet-EVs were more numerous 
than those derived from any other cell type measured, and those 
bearing CD142 (tissue factor) were rarely detected (Figure 5D). 
To characterize WBC-EVs, various cell lineage and activation 
markers were examined (Figure  5E). EVs bearing markers of 
T cells (CD3), B cells (CD19), monocyte/NK cells (CD16), and 
granulocytes (CD66b) were all detected. The adhesion molecule 
CD15 was detected at higher levels than the adhesion molecule 
CD62L (L-selectin), though overall there were insignificant 
differences in expression of various WBC markers on EVs in 
healthy subjects. These data demonstrate that EVs from different 
cell subtypes can be distinguished by flow cytometry and that 
WBC-EVs are present at low-level in healthy subjects’ plasma.
Predictors of Mortality in critically ill 
Patients
As part of the ABLE study to analyze the effect of RBC unit stor-
age on clinical outcomes in transfused, critically ill patients (30), 
FigUre 4 | Role of scavenger receptors and TLRs in extracellular vesicle (EV)-monocyte binding. Peripheral blood mononuclear cells (PBMCs) (500,000) from 4 
healthy donors were cultured unstimulated or incubated with 100 µL of PKH26 labeled EVs derived from plasma of 4 other healthy donors for 24 h. (a) PBMCs 
were incubated with EVs alone, or EVs pre-incubated with annexin V (1.0 µg/mL) or anti-phosphatidylserine (PS) antibody (1.0 µg/mL) for 1 h and added to PBMCs, 
or PBMCs were pre-incubated for 1 h with other antibodies noted on the x-axis at 1.0 µg/mL and added to PBMCs. After 24 h cells were stained with anti-CD14 
and monocyte-EV binding was analyzed. (B) PBMCs were pre-incubated for 1 h with the noted TLR antagonists before incubation with EVs for 24 h as above.  
(c) PBMCs were incubated with EVs derived from red blood cell (RBC) units stored for 42 days, and binding inhibitors were added as above. (D) Binding of EVs 
derived from four different purified cell types to monocytes was assessed with or without pre-incubation of PBMCs with anti-CD36 antibody. EV binding inhibition 
conditions were compared with the EV alone condition by ANOVA with Dunnett’s post-test (a–c) or by t-test (D) (*p < 0.05, **p < 0.01, and ***p < 0.001).
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serial samples were collected from 100 subjects randomized to 
receive RBC units that had been stored for a shorter or longer 
period. These subjects were 95% medical admissions, were 50% 
female, and had a median age of 67. These samples were tested 
for an array of 16 coagulation, 27 cytokine, 3 immune cell, and 14 
EV markers. The ABLE study found no effect of RBC unit storage 
age on mortality or other clinical outcomes, and the longitudinal 
analysis of the relationship of these markers with RBC unit age 
is the subject of a manuscript in preparation. For this study, we 
analyzed the 100 subjects in aggregate to determine if immune 
or coagulation markers in samples collected at ICU admission, 
pre-transfusion predicted subsequent 28-day mortality, which 
FigUre 5 | Extracellular vesicles (EVs) in healthy controls and as predictors of mortality in intensive care unit patients. (a) Gating strategy for EVs shows detection 
of beads sized 100–1,000 nm on the SSC channel in the left panel, and gating of EVs in the right panel. Representative flow cytometry plots for (B) red blood cell 
(RBC) and (c) granulocyte markers are shown. (D) Levels of EVs were measured in 48 healthy control subjects using a panel of markers to identify EVs derived from 
platelets (CD41a and CD62P), RBCs (CD235a and CD108a), and endothelial cells (CD142). CD41a+ EVs were significantly more abundant than all other populations 
(p < 0.0001); all other significant differences are noted on the graph. (e) White blood cell (WBC)-EVs were characterized based on cell of origin (CD3, CD16, CD19, 
CD66b) and expression of co-stimulatory (CD28 and CD154), and adhesion molecules (CD62L, CD11b, and CD15). (F) Of 62 parameters measured at baseline in 
100 critically ill subjects, the 6 associated with 28-day mortality are shown, including EVs expressing four markers (CD15, CD11b, CD62P, and CD66b) (*p < 0.05, 
**p < 0.01, ***p < 0.001, and ****p < 0.0001).
11
Danesh et al. Monocyte Responses to EV Subtypes
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 956
was 22% in these subjects (Table 1). Elevated levels of six fac-
tors upon intensive care unit (ICU) admission were associated 
with subsequent mortality: cystatin C, TPA, and EVs bearing the 
markers CD15, CD11b, CD62P, or CD66b (Figure 5F).
DiscUssiOn
In this article, we show that plasma-EVs biased primary mono-
cytes toward an M1 profile and led to secretion of inflammatory 
mediators. Inspection of EVs from purified cell populations 
revealed that monocyte-, granulocyte-, and endothelial-EVs drove 
a pro-inflammatory monocyte response, with granulocyte-EVs 
inducing the broadest and highest magnitude response. In addi-
tion, platelet-EVs were the only population to induce monocyte 
production of the anti-inflammatory cytokine TGF-β, and RBC- 
EVs did not regulate cytokines and chemokines that we measured. 
The scavenger receptor CD36 is a potential receptor for RBC- 
EVs but not for the other EV subtypes tested. Finally, we showed 
that CD66b+ granulocyte-EVs are early predictors of mortality 
in ICU patients.
TaBle 1 | Baseline predictors of mortality.
coagulation cytokines extracellular vesicles
Parameter p Value hr (cb) Parameter p Value hr (cb) Parameter p Value hr (cb)
PT 0.33 1.02 (0.97–1.08) GM-CSF 0.059 0.70 (0.48–1.01) EV concentration 0.83 1.04 (0.74–1.45)
PTT 0.085 1.01 (0.999–1.017) IFN-γ 0.84 0.97 (0.73–1.29) Annexin V 0.85 0.98 (0.80–1.20)
D-dimer 0.7 1.04 (0.86–1.25) IL-10 0.84 1.03 (0.77–1.37) CD3 0.78 1.04 (0.79–1.37)
Factor II 0.28 0.99 (0.97–1.01) IL-12p70 0.84 1.06 (0.58–1.96) CD14 0.56 1.06 (0.88–1.27)
Factor V 0.21 0.99 (0.98–1.004) IL-17A 0.3 0.81 (0.54–1.21) CD16 0.62 0.93 (0.70–1.24)
Factor VII 0.28 0.75 (0.45–1.26) IL-1β 0.89 1.06 (0.45–2.49) CD19 0.8 0.97 (0.76–1.24)
Factor VIII40 0.63 1.00 (0.998–1.003) IL-2 0.62 0.85 (0.45–1.61) CD28 0.22 1.11 (0.94–1.31)
Factor IX 0.96 1.00 (0.99–1.01) IL-21 0.31 0.73 (0.40–1.34) CD152 0.59 0.93 (0.72–1.21)
Factor X 0.95 0.99 (0.98–1.01) IL-23 0.84 0.98 (0.78–1.22) CD41a 0.32 1.12 (0.89–1.41)
ATIII 0.74 1.03 (0.88–1.20) IL-6 0.62 0.92 (0.67–1.27) CD62L 0.091 1.22 (0.97–1.55)
PC 0.18 0.90 (0.78–1.05) IL-7 0.69 1.01 (0.94–1.09) CD108a 0.71 0.94 (0.70–1.28)
FIB 0.26 0.99 (0.98–1.01) IL-8 0.62 1.10 (0.75–1.61) CD235a 0.98 1.00 (0.76–1.31)
TM 0.69 1.18 (0.51–2.73) ITAC 0.92 0.98 (0.70–1.38) CD11b 0.01 1.44 (1.09–1.91)
ECPR 0.72 1.01 (0.94–1.10) MIP-1α 0.19 0.73 (0.46–1.17) CD15 0.021 1.25 (1.03–1.52)
TPA 0.011 1.57 (1.10–2.22) MIP-1β 0.24 0.70 (0.38–1.26) CD62P 0.008 1.34 (1.08–1.66)
PAI-1 0.27 1.14 (0.93–1.44) TNF-α 0.81 1.06 (0.67–1.67) CD66b 0.001 1.60 (1.20–2.15)
EGF 0.82 1.03 (0.77–1.39)
FGF 0.82 0.97 (0.72–1.30) Cellular immunity
VEGF 0.29 1.10 (0.92–1.31) Treg 0.098 1.25 (0.96–1.63)
β2-Microglobulin 0.28 1.12 (0.91–1.31) CD4-IL-7 0.21 2.30 (0.63–8.37)
Cystatin C <0.0001 1.04 (1.02–1.07) CD8-IFN-γ 0.3 0.98 (0.94–1.02)
MPO 0.26 1.19 (0.88–1.59)
PDFG AB/BB 0.59 1.05 (0.88–1.26)
RANTES 0.47 0.91 (0.70–1.18)
sICAM-1 0.57 1.01 (0.98–1.04)
sVCAM-1 0.084 1.02 (1.00–1.04)
HR, hazard ratio; cb, confidence bound; PAI-1, plasminogen activator inhibitor type-1; TPA, tissue plasminogen activator; EV, extracellular vesicle.
Significant values in bold.
HRs reflect the change in the hazard that is associated with one unit of change in particular variables except as noted below.
10 units of change: GM-CSF, IFN-γ, IL-10, IL-23, IL-6, IL-8, ITAC, EGF, FGF, and VEGF.
100 units of change: PDFG AA/BB, CD3, CD14, CD16, CD19, CD28, CD152, CD62L, CD108a, CD11b, CD15, and CD66b.
1,000 units of change: RANTES, CD235a, CD62P, and annexin V.
10,000 units of change: MPO, sICAM-1, CD41a, and EV concentration.
1 million units of change: cystatin C.
10 million units of change: β2-microglobulin.
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Knowing that plasma-EVs are comprised of a heterogeneous 
mix of subtypes derived from distinct cells of origin (40–42), and 
to better understand which EVs in plasma bias monocytes to a pro- 
inflammatory phenotype, EVs were prepared from purified cell 
populations using routine procedures in a blood bank setting 
(RBC- and platelet-EVs), or by culturing unstimulated cells (mono-
cyte-, granulocyte-, and endothelial-EVs) to avoid the effect of 
mitogens on EV cargo (43). Granulocyte-EVs were found to be 
the most potent pro-inflammatory agents of the EV subtypes 
studied, followed by monocyte- and endothelial-EVs in pro-
inflammatory activity in our in vitro assays. Granulocyte-EVs have 
also been described to augment or suppress immune response 
(42, 43). Eken et al. have reported that EVs released by granu-
locytes induce a MerTK-dependent anti-inflammatory pathway 
in monocyte-derived macrophages (44). One difference between 
that study and the current work is that they stimulated purified 
granulocytes with fMLP to generate EVs. This stimulation could 
have affected the EV cargo and composition compared with 
EVs that are released during physiologic conditions or from 
granulocytes that were not stimulated (45). In contrast to the 
pro-inflammatory EVs, platelet-EVs induced TGF-β secretion by 
monocytes. TGF-β is a multifunctional cytokine with a dominant 
immunosuppressive activity. While it plays a positive role in 
tissue repair and in the control of autoimmune and infectious 
diseases, its upregulation may increase the growth of tumor cells 
(46). Platelet-EVs may have therapeutic value in tissue repair and 
downregulating the immune system in autoimmune diseases.
After demonstrating that plasma-EVs activated monocytes, 
we searched for antibodies that could block EV–monocyte bind-
ing. The RNA-Seq data showed the downregulation of a cluster of 
scavenger receptors on monocytes followed by their stimulation 
with total EVs. Two well-known scavenger receptors that were 
downregulated (CD36 and CD163) and one whose gene tran-
scription did not change (CD206) were selected for functional 
studies. Blockade of these receptors did not affect the binding of 
plasma-EVs to monocytes, though anti-CD36 antibody blocked 
RBC-EV binding to monocytes. A prior study has shown that 
endothelial-EVs bind to the scavenger receptor CD36 on platelets 
and contribute to thrombosis in mice (25). We found that the 
scavenger receptors CD36 and CD163 were downregulated 
on the cell surface of monocytes stimulated with plasma-EVs; 
however, a binding inhibition assay showed that only CD36 was 
involved in RBC-EV binding to monocytes. Given the relative 
lack of effect of RBC-EVs in our monocyte stimulation assays, 
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it is unclear how effective CD36 blockade would be in regulat-
ing immune changes potentially induced by transfusions rich in 
RBC-EVs, though other investigators have described RBC-EVs 
as having immune suppressive activity (9). Blockade of CD9, 
CD81, CD54, CD11a, CD51, and CD61 is reported to reduce EV 
uptake by dendritic cells (22). The interaction of lectin family 
members such as CD205 and CD209 has also been studied, and 
their blockade leads to reduced EV uptake (21, 23). In general, EV 
uptake cannot be prevented completely by blockade of one recep-
tor, suggesting that several receptors are involved (12, 19, 21–24). 
TLRs have also been described to play a role in EV uptake. We 
tested antibodies against TLR1, TLR2, and TLR4, and they did 
not block EV–monocyte binding. It has been shown that tumor-
exosomes control the expansion of myeloid-derived suppressor 
cells through TLR2 and not TLR4, which leads to secretion of 
IL-6 and suppression of CD8+ T cells (18). However, it was found 
in another study that stimulation of the monocytic cell line THP1 
with tumor-exosomes induced TNF-α, IL-1β, and IL-6 through 
TLR2 and TLR4 signaling (17).
In our ex vivo study on plasma samples from ICU patients, 
a panel of 43 cytokines and coagulation factors was examined, 
and only TPA and cystatin C were associated with mortality risk 
(47–52). TPA is involved with fibrinolysis and has been reported to 
be a marker for subsequent mortality in subjects hospitalized for 
acute dyspnea (50). Its significant release by endothelial cells after 
traumatic injury has been shown to result in excessive blee ding 
and hyperfibrinolysis, which are known risk factors for mortality 
(48, 49). Cystatin C is a cysteine protease inhibitor that plays a 
role in catabolism of proteins, and it has been widely described 
as being associated with mortality risk in various disease states 
(47, 51, 52). In addition, 4 of the 14 EV markers tested were asso- 
ciated with increased death risk in this population of critically 
ill patients who primarily presented with medical as opposed to 
surgical diagnoses (30). The existing literature is relatively scarce 
describing the prognostic potential of EVs as predictors of mortal-
ity. Our results indicate that CD66b, CD15, CD11b, and CD62P 
EVs were predictors of mortality in our cohort of patients. Of 
these, CD66b is the most specific and is a marker for granulocytes 
(53). CD15 is expressed on granulocytes and monocytes (54), 
and given that levels of the monocyte markers CD14 and CD16 
were not associated with risk of death, it is likely that the CD15 
EVs arose from granulocytes rather than monocytes. CD11b is 
expressed on many cell types including granulocytes, monocytes, 
and lymphocytes (55), so while elevated CD11b-expressing EVs 
is consistent with a granulocyte cell of origin, this marker is not 
specific. CD62P is an endothelial and platelet marker (56), and 
in this study EVs bearing the platelet marker CD41a were not 
associated with mortality risk. CD41a-expressing EVs have been 
reported to be positively or negatively associated with mortality 
in prior studies (57–59). Endothelial-EV markers were not mea-
sured in this study, though it is possible that CD62P EVs were 
derived from endothelial cells. The upregulation of endothelial-
EVs has been described in patients with systemic inflammation 
due to sickle cell disease (27). Given the exploratory nature of 
the large panel of analytes studied, correlations were not corre-
cted for multiple comparisons. The pattern of predominantly 
granulocyte-EVs correlating with mortality risk is suggestive 
that the correlations were not random, though future studies 
will be needed to confirm the association. Of note, WBC- and 
granulocyte-EVs were recently reported to be associated with 
subsequent mortality in a population of critically ill burn patients, 
increasing confidence in the validity of the association (29). Our 
data are consistent with a model in which EVs from various cell 
types signal circulating monocytes, which can synthesize these 
FigUre 6 | Hypothetical model of extracellular vesicle (EV) interaction with monocytes. In this model, acute infection results in augmented release of EVs from cells, 
particularly granulocytes, which are ingested by monocytes. Activated monocytes can then differentiate and migrate to tissues, which can increase tissue 
inflammation and damage. Abbreviations: PMN, polymorphonuclear cell (granulocyte); Plt, platelet.
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signals to become activated and potentially participate in tissue 
damage (Figure 6).
Here, we have shown by gene expression analysis that incu-
bation of monocytes with EVs polarized monocytes toward a 
pro-inflammatory state. Of five EV subtypes that were tested, 
monocyte-, endothelial-, and granulocyte-EVs induced production 
of pro-inflammatory cytokines in monocytes, and granulocyte-
EVs were the most potent inflammation trigger. Platelet-EVs 
induced production of the anti-inflammatory cytokine TGF-β 
and GM-CSF, and RBC-EVs did not regulate cytokines and 
chemokines that were measured. We demonstrated a role for 
the scavenger receptor CD36 in the binding of RBC-EVs to 
monocytes. Finally, we have shown granulocyte-EVs (expres-
sing CD66b) were early predictors of mortality in ICU patients. 
Characterization of anti-inflammatory subtypes of EVs may have 
therapeutic applications in inflammatory diseases including cri- 
tical illness, and pro-inflammatory EVs could potentially be 
harnessed as vaccine adjuvants or targeted for blockade to reduce 
inflammation during critical illness.
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